Silver Spring, Md.-based United Therapeutics Corp. and the FDA are duking it out in court over whether the agency improperly denied the biotechnology company seven years of orphan drug exclusivity for its drug Orenitram.
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company’s anti-influenza immune globulin being developed as an intravenous treatment for serious illness caused by influenza A infection in hospitalized patients.
Making predictions can be a tricky business. Nevertheless, Xconomy recently brought together some of San Diego’s most prominent life sciences leaders to offer their vision for what the regional biotech cluster will be like in five years.
Scott Gottlieb seems like the pharmaceutical industry’s idea of a dream FDA Commissioner, with pharma ties and an ideological bent toward deregulation.
Centrexion Therapeutics, a Boston-based startup led by ex-Pfizer CEO Jeff Kindler, just raised $67 million to bring its painkiller drug into Phase III trials. If it works, the treatment should appease regulators concerned with addiction problems, as the drug is a non-opioid and non-steroid way to treat pain.
Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced the successful completion of a $67 million Series D financing.
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners. In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors.
I expect progress. Here’s my list of major trends and issues that will affect the lives of cancer patients in 2018:
The grants came through the National Institute of Allergy and Infectious Diseases and the National Science Foundation.
Join us on Thursday, January 11 for the 2017-18 Spring Term FAES Graduate School Open House to meet and mingle with FAES faculty. Bring yourself, a friend, and your questions about registering for the Spring 2018 courses. The event will be held in the FAES Academic Center, Building 10, NIH, Bethesda, MD, 4:00 – 6:00 PM. Light refreshments will be served!